The American Journal of Surgical Pathology · 2020 · 238 citations · 25 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaTumor PathologyAntibody CharacterizationAntibody DiscoveryDiagnostic Antibody DesignDiagnostic Monoclonal AntibodiesSoft Tissue SarcomasTumor AntigensAntibodiesChromatin Immunoprecipitation SequencingCytogenetic AberrationsCytogenetic AbnormalitiesDifferential StainingSarcoma ClassificationSarcoma PathologySoft Tissue Sarcoma Histopathology
Synovial sarcoma (SS), an aggressive soft tissue sarcoma with a predilection for the extremities of young adults, harbors the pathognomonic t(X;18)(p11;q11) translocation, resulting in SS18-SSX rearrangements. SS includes monophasic, biphasic, and poorly differentiated variants, which show considerable histologic overlap with a range of other tumor types, making the diagnosis challenging on limited biopsies. Immunohistochemistry (IHC) is routinely used in the differential diagnosis; however, presently available markers lack specificity. Thus, cytogenetic or molecular genetic techniques are often employed to confirm the diagnosis. Here, we report the development and characterization of 2 novel antibodies: an SS18-SSX fusion-specific antibody (E9X9V, designed to the breakpoint) as well as an SSX-specific antibody (E5A2C, designed to the SSX C-terminus). We validated the selectivity and specificity of the antibodies using immunoblotting, immunoprecipitation, and chromatin immunoprecipitation followed by next-generation sequencing in SS cell lines and demonstrated that both antibodies capture SS18-SSX on chromatin at established target sites (eg, TLE1 and BCL2) genome-wide. Using IHC in whole sections from 400 tumors including 100 genetically confirmed cases of SS and 300 histologic mimics, the SS18-SSX fusion-specific antibody revealed strong diffuse nuclear staining in 95 of 100 (95%) SS cases, whereas none of the 300 control tumors showed any staining. The SSX antibody showed strong diffuse nuclear staining in all 100 (100%) SS cases; 13 (4%) of the 300 other tumors were also positive, 5 of which displayed >50% nuclear staining. In summary, a novel SS18-SSX fusion-specific antibody is highly sensitive (95%) and specific (100%) for SS, and an antibody to the SSX C-terminus is also highly sensitive (100%), but slightly less specific (96%). IHC using the SS18-SSX antibody could replace molecular genetic or cytogenetic testing in most cases, and these reagents together will also provide the research community with valuable tools for further biochemical and genomic interrogation of the SS18-SSX fusion protein.
25
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Ron Firestein, Adam J. Bass, So Young Kim et al. · Nature · 2008 · 679 citations · Full text
Medicine, Cell Biology, Oncology +14
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl, T. Khanh, Priyanka Shivdasani et al. · JCI Insight · 2016 · 448 citations · Full text
Medicine, Pathology, Cancer Genetics +16